Cravatex (509472.BO) Stock Price
Cravatex Price
Revenue has compounded at 3.3% per year over the past 15 years to 1.51 B INR. Earnings per share have declined at 4.5% per year over the last 15 years. Cravatex's net margin stands at 4.5%, up from -3.3% several years earlier. Cravatex currently offers a dividend yield of about 3.63%. The payout ratio is around 28% of earnings. The dividend has grown at 11.3% per year over the past 15 years.
Cravatex stock price
Cravatex business model & stock analysis
Frequently asked questions about Cravatex
Converted at the current exchange rate, the Cravatex share trades at 3.18 EUR (344.15 INR).
The revenue of Cravatex is 1.51 B INR. This figure is based on current financial data and reflects the company's business performance.
The profit of Cravatex is 67.97 M INR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Cravatex is currently 13.09. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Cravatex stock.
The price-to-sales ratio (P/S) of Cravatex is currently 0.59. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Cravatex stock.
The Eulerpool Quality Score for Cravatex is 1/10.
The ISIN of Cravatex is INE145E01017. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Cravatex is 509472.BO. The ticker symbol is used to trade Cravatex shares on the stock exchange.
Cravatex stock
Cravatex Peer Group
Cravatex FIGI
All fundamentals and in-depth analysis of Cravatex
Our stock analysis for Cravatex stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cravatex. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.